Insulin resistance and the endothelium

被引：40

作者：

Quiñones M.J. ^{[1
]}

Nicholas S.B. ^{[1
]}

Lyon C.J. ^{[1
]}

机构：

[1] David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, CA 90095

来源：

Current Diabetes Reports | 2005年 / 5卷 / 4期

关键词：

Simvastatin; Endothelial Dysfunction; Endothelial Function; Rosiglitazone; Myocardial Blood Flow;

D O I：

10.1007/s11892-005-0018-z

中图分类号：

学科分类号：

摘要：

Type 2 diabetes is a cardiovascular disease equivalent that is associated with accelerated atherosclerosis and significant mortality. However, the metabolic syndrome and prediabetes are associated with increased cardiovascular mortality, indicating that atherogenic vascular changes begin prior to the onset of overt diabetes. At the core of diabetes and the metabolic syndrome is insulin resistance (IR), which sets the stage for dyslipidemia, hypertension, and inflammation. Endothelial dysfunction is the first stage of the atherosclerosis process and results from exposure to cardiovascular risk factors, such as IR and diabetes. IR and atherosclerosis follow parallel paths as they progress in severity. Thiazolidinediones, angiotensin-converting enzyme inhibitors, angiotensin receptor-AT I blockers, and statins are widely used in the treatment of diabetes. Emerging evidence indicates that these pharmacologic agents have added mechanisms of action, especially on the endothelium and in the prevention of diabetes. Copyright © 2005 by Current Science Inc.

引用

页码：246 / 253

页数：7

共 69 条

[1]

Flegal K.M., Carroll M.D., Ogden C.L., Johnson C.L., Prevalence and trends in obesity among US adults, 1999-2000, JAMA, 288, pp. 1723-1727, (2002)

[2]

Harris M., Flegal K., Cowie C., Et al., Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults, Diabetes Care, 21, pp. 518-524, (1998)

[3]

Haffner S.M., Miettinen H., Insulin resistance implications for type II diabetes mellitus and coronary heart disease, Am. J. Med., 103, pp. 152-162, (1997)

[4]

Gu K., Cowie C.C., Harris M.I., Diabetes and decline in heart disease mortality in US adults, JAMA, 281, pp. 1291-1297, (1999)

[5]

Haffner S.M., Lehto S., Ronnemaa T., Et al., Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction, N. Engl. J. Med., 339, pp. 229-234, (1998)

[6]

Malmberg K., Yusuf S., Gerstein H.C., Et al., Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: Results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry, Circulation, 102, pp. 1014-1019, (2000)

[7]

Haffner S.M., Agostino Jr. R.D., Saad M.F., Et al., Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study), Am. J. Cardiol., 85, pp. 1395-1400, (2000)

[8]

JAMA, 285, pp. 2486-2497, (2001)

[9]

Sung C., Arleth A., Storer B., Ohlstein E., Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle, J. Pharmacol. Exp. Ther., 271, pp. 429-437, (1994)

[10]

Hirata Y., Takagi Y., Fukuda Y., Marumo F., Endothelin is a potent mitogen for rat vascular smooth muscle cells, Atherosclerosis, 78, pp. 225-228, (1989)

← 1 2 3 4 5 6 7 →